Local News: Bakersfield, CA 

 | 

Sign Up

 | 

Sign In

Advertisment

Endo Pharmaceuticals Holdings

Endo Pharmaceuticals Holdings News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make Endo Pharmaceuticals Holdings News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

RSS icon mobile icon

Endo Pharmaceuticals Holdings News

News on Endo Pharmaceuticals Holdings continually updated from thousands of sources around the net.

4 hrs ago | TheStreet.com

FedEx: Analysts' Upgrades, Dowgrades

CHANGE IN RATINGS Apple initiated at Calyon Securities with a Buy rating and $260 price target.

Comment?

Related Topix: iPhone, Baidu, Biotech, Medicine, Healthcare Industry

Mon Dec 07, 2009

LIBN Breaking News

Endo Pharma downgraded on drug delay

An Oppenheimer analyst downgraded shares of Endo Pharmaceuticals Holdings Inc. Monday, pointing to regulatory delays for two of Endo's testosterone drug candidates.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Fri Dec 04, 2009

MarketWatch

Biotech Stocks: Endo falls on FDA move; Generex rallies

Drug stocks gained ground Thursday afternoon while shares of Endo Pharmaceuticals fell on news that U.S. regulators have declined to approve its hormone therapy Aveed for the treatment of low testosterone in men.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Generex Biotechnology, Food and Drug Administration, Insulin (generic), Humulin, Novolin, Medication, Human Genome Sciences

Thu Dec 03, 2009

Market Watch

Drug stocks gain; Endo shares retreat

The NYSE Arca Pharmaceutical Index /quotes/comstock/10t!drg.x was up 0.4% to 313.26 and the NYSE Arca Biotechnology Index /quotes/comstock/10t!btk.x climbed 0.6% to 916.22. Endo shares were off 5% at $21.30. /quotes/comstock/15*!endp /quotes/nls/endp Endo Pharmaceuticals... /marketstate/country/ The market is open The market is closed $ 21.02 ...

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

BioSpace

Us Fda Declines to Approve Endo Pharmaceuticals Testosterone Drug

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration regarding the New Drug Application for its extended-duration testosterone undecanoate injection, AVEED , for men diagnosed with low testosterone.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration, Marketing, Health, Pain, Prostate Cancer, Arthritis

Tue Dec 01, 2009

Seeking Alpha

December's Defensive Game Plan for Biotech

Historically, playing the drug makers in December has proven to be a safe bet. December ranks first, above August and September, as the best performing month for the iShares Nasdaq Biotechnology ETF with average gains of about 8%. Outlined below is a defensive game plan that might help investors beat the benchmark.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Healthcare Industry, Lymphoma, Health

Fri Nov 27, 2009

Philadelphia Business Journal

Endo Pharmaceuticals in position for deals

David Holveck, in his first full year as CEO of Endo Pharmaceuticals , has overseen the company's purchase of one drug company and signed two licensing agreements in three deals with a combined value of more than $900 million.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Mon Nov 23, 2009

Bloomberg

King Pharmaceuticals May Climb as Battered Drug Firms Lure Private Equity

King Pharmaceuticals Inc., LifePoint Hospitals Inc. and Endo Pharmaceuticals Holdings Inc.

Comment?

Related Topix: Biotech, King Pharmaceuticals, Medicine, Healthcare Industry, Hospital Administration, LifePoint Hospitals, Insurance, Credit Suisse Group, Chadds Ford, PA, Ims Health, Computers, Advertising

Sat Nov 14, 2009

Philadelphia Business Journal

Biotech 2009 almost here

Biotech 2009, the annual conference co-hosted by Pennsylvania Bio and BIO NJ, will take place Monday and Tuesday and feature keynote speakers David Holveck and Fred Hassan.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Schering Plough, Philadelphia, PA

Thu Nov 12, 2009

Drug Store News

Endo settles with LecTec

CHADDS FORD,A Pa. Generic drug maker Endo Pharmaceuticals has reached a settlement with the manufacturer of a pain drug, Endo announced Thursday.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Health, Pain, Xylocaine, Lidocaine (generic), Medication, Chickenpox

Mon Nov 09, 2009

About.com

Testosterone Boosters: Big with Boomers

FDA concerns about the safety of two testosterone boosters from Endo Pharmaceuticals may delay their approval, but safety concerns haven't kept testosterone sales from increasing 25 percent in the past year , according Business Week .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Erectile Dysfunction, Health

Sat Nov 07, 2009

BioSpace

RXi Pharmaceuticals Appoints as CEO

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference , today announced that Noah D. Beerman has joined the company as its new President and Chief Executive Officer.

Comment?

Related Topix: Biotech, Medicine, Indevus Pharmaceuticals, Healthcare Industry

Fri Nov 06, 2009

Bioscience Technology

Bioniche Life Sciences Q1 loss widens to $6.8M from $3.3 as sales dip

Bioniche Life Sciences Inc.'s first-quarter loss more than doubled as revenues slightly dipped, the biotechnology company said Friday.

Comment?

Related Topix: Canada, Biotech, Medicine, Healthcare Industry

Medical News

Bioniche Life Sciences announces financial results for its Fiscal 2010 first-quarter

Bioniche Life Sciences Inc. , a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 first quarter, ended September 30, 2009.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, bladder cancer, Health

Thu Nov 05, 2009

The Biotech Stock Blog

Penwest Pharmaceuticals Co. Q3 2009 Earnings Call Transcript

Penwest Pharmaceuticals Co. November 5, 2009 11:00 am ET Executives Jennifer Good - President and CEO Frank Muscolo - Corporate Controller and Chief Accounting Officer Analysts David Watson Scott Henry - Roth Capital Presentation Operator At this time, I would like to welcome everyone to the Penwest third quarter 2009 financial results conference ...

Comment?

Related Topix: Biotech, Medicine, Penwest Pharmaceuticals, Healthcare Industry

Fri Oct 30, 2009

Customer Interaction Solutions

BUYINS.NET: Endo Pharmaceuticals (ENDP) Up After BUYINS.NET Report Predicted Strength After Earnings

BUYINS.NET, www.buyins.net, a provider of unique trading technologies, released a report on October 27, 2009 at 10:32 am PDT stating that Endo Pharmaceuticals was expected to be higher after its earnings were released before the open on Thursday, October 29, 2009.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Financial Markets

Thu Oct 29, 2009

BusinessWeek

Testosterone Is Sure Looking Virile

When Endo Pharmaceuticals acquired two experimental testosterone products earlier this year, CEO David P. Holveck predicted that safety issues might delay approval by the U.S. Food & Drug Administration.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Healthcare Law, Food and Drug Administration, Law, Fatigue, Health, Marketing

Tue Oct 27, 2009

Drugs.com

Endo Pharmaceuticals Gives Update on Regulatory Status of Fortesta

Endo Pharmaceuticals today announced that it received a Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application for Fortesta 2% Gel for men diagnosed with low testosterone , also known as hypogonadism.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration, Health, Pain, Prostate Cancer, Arthritis

Wed Oct 21, 2009

The Herald

Drug approval delay causes ProStrakan dip

Shares in ProStrakan, the Borders-based speciality pharmaceutical group, plunged almost 5% yesterday after it emerged US health regulators delayed approval of its cure-all for the male menopause.

Comment?

Related Topix: World News, United Kingdom, The Scottish Borders County, Scotland, Biotech, Medicine, Healthcare Industry

Tue Oct 20, 2009

Philadelphia Business Journal

Endo to respond to Fortesta questions

Endo Pharmaceuticals said Monday it expects to respond to the Food and Drug Administration's questions about the company's new drug application for the low testosterone treatment Fortesta by mid-2010. Fortesta is an experimental gel product for men diagnosed with low testosterone, also known as hypogonadism.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Chadds Ford, PA

Bakersfield Jobs

Also on Topix